Detection of metastatic cancer cells in mesentery of colorectal cancer patients

Xue-Lai Luo, Da-Xing Xie, Jian-Xin Wu, An-Ding Wu, Zong-Qing Ge, Hai-Jie Li, Jun-Bo Hu, Zhi-Xin Cao, Jian-Ping Gong

AIM
To detect the existence of isolated cancer cells in the mesentery of colorectum (named as Metastasis V), and investigate its clinical significance in colorectal cancer (CRC) patients.

METHODS
Sixty-three CRC patients who received radical excision between January 2012 and September 2015 were included. All the patients underwent laparoscopy-assisted radical colorectomy or proctectomy [with complete mesocolic excision (CME) or total mesorectal excision (TME)] with R0 dissections at the Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. The location and size of the primary lesions were recorded immediately after the tumor was removed, with the surrounding mesenterium completely separated along the intestinal wall. Each dissected mesentery sample was analyzed for hematoxylin-eosin staining and immunohistochemistry using cytokeratin 19 antibody. Image Pro Plus Software 6.0 (Media Cybernetics, CA, United States) was used for image analysis.

Results
Metastasis V cells were detected in 32% (20/63) of CRC patients. The presence of metastasis V cells was associated with a significantly lower disease-free survival rate (P=0.01).

Conclusion
The detection of isolated cancer cells in the mesentery of colorectum (metastasis V) is a significant predictor of disease recurrence in CRC patients.

Observational Study
Detection of metastatic cancer cells in mesentery of colorectal cancer patients

Xue-Lai Luo, Da-Xing Xie, Jian-Xin Wu, An-Ding Wu, Zong-Qing Ge, Hai-Jie Li, Jun-Bo Hu, Zhi-Xin Cao, Jian-Ping Gong

Support by the National Natural Science Foundation of China, No. 81572861, No. 81302309 and No. 81372324.

Institutional review board statement: All procedures performed in the study were in accordance with the ethical standards of Tongji Hospital Ethics Committee, Wuhan, China.

Informed consent statement: Informed consent was obtained from all participants included in the study.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Correspondence to: Jian-Ping Gong, MD, PhD, Tongji Cancer Research Institute, Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Av., Wuhan 430030, Hubei Province, China. jgp@gmail.com

Telephone: +86-27-83665275
Fax: +86-27-83662696

Received: November 2, 2016
Peer-review started: November 4, 2016
First decision: January 19, 2017
Revised: March 21, 2017
Accepted: May 19, 2017
Article in press: May 19, 2017
Published online: September 14, 2017

Abstract
AIM
To detect the existence of isolated cancer cells in the mesentery of colorectum (named as Metastasis V), and investigate its clinical significance in colorectal cancer (CRC) patients.

METHODS
Sixty-three CRC patients who received radical excision between January 2012 and September 2015 were included. All the patients underwent laparoscopy-assisted radical colorectomy or proctectomy [with complete mesocolic excision (CME) or total mesorectal excision (TME)] with R0 dissections at the Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. The location and size of the primary lesions were recorded immediately after the tumor was removed, with the surrounding mesenterium completely separated along the intestinal wall. Each dissected mesentery sample was analyzed for hematoxylin-eosin staining and immunohistochemistry using cytokeratin 19 antibody. Image Pro Plus Software 6.0 (Media Cybernetics, CA, United States) was used for image analysis.

Results
Metastasis V cells were detected in 32% (20/63) of CRC patients. The presence of metastasis V cells was associated with a significantly lower disease-free survival rate (P=0.01).

Conclusion
The detection of isolated cancer cells in the mesentery of colorectum (metastasis V) is a significant predictor of disease recurrence in CRC patients.
to semi-quantitatively measure the concentration of the cytokeratin 19 immunohistochemistry. The correlation between metastasis found in mesentery and clinicopathological characteristics was examined. The prognosis of patients was also evaluated by preoperative serum CEA level.

RESULTS
Metastasis V was detected in 14 of 63 (22.2%) CRC patients who underwent laparoscopy-assisted radical colectomy or proctectomy (with CME or TME) with R0 dissection in our hospital between January 2012 and September 2015. There was no significant difference in age, gender, tumor size, and tumor location in patients with Metastasis V (P > 0.05). Metastasis V was more likely to occur in poorly differentiated tumor (5/11; 45.5%) than moderately (8/46; 17.4%) and well-differentiated one (1/6; 16.7%). The Metastasis V in N2 stage (9/14; 64.3%) was more frequent that in the N0 stage (3/35; 8.6%) or N1 stages (2/14; 14.3%). In addition, Metastasis V was positively related to the tumor invasive depth (T1:0/1, 0%; T2:1/12, 8.3%; T3:7/39, 17.9%; T4:6/11, 54.5%). Furthermore, preoperative serum CEA level in Metastasis V-positive patients was significantly higher than in Metastasis V-negative patients (4.27 ng/mL vs 3.00 ng/mL).

CONCLUSION
Metastasis V might be associated with a poor prognosis of CRC patients.

Key words: Colorectal cancer; Colorectal mesentery; Serum CEA level; Radical surgery; Metastasis V

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Local-regional recurrence of colorectal cancer (CRC) is common in patients who received R0 resection. Our previous study proposed a novel type of metastasis designated as “Metastasis V” in gastric cancer. Metastasis V is defined as the appearance of cancer cells in the mesentery in broad sense, and may be a risk factor for the poor prognosis after radical surgery. In this study, Metastasis V was also detected in the mesentery of colorectum, and it might be associated with the poor prognosis of CRC patients.

Luo XL, Xie DX, Wu JX, Wu AD, Ge ZQ, Li HJ, Hu JB, Cao ZX, Gong JP. Detection of metastatic cancer cells in mesentery of colorectal cancer patients. World J Gastroenterol 2017; 23(34): 6315-6320. Available from: URL: http://www.wjgnet.com/1007-9327/full/v23/i34/6315.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i34.6315

INTRODUCTION
Three decades ago, RJ Heald introduced the total mesorectal excision (TME) in the treatment of rectal cancer[1]. Subsequently, complete mesocolic excision (CME) was popularized by W Hoehenbuerg to reduce tumor relapse and improve prognosis in colon cancer patients[2]. These new approaches greatly contributed to the complete mesentery excision and improved lymph node harvest. Furthermore, with the development of surgical technology, neo-adjuvant chemotherapy and efficient perioperative management, the prognosis of patients with colorectal cancer (CRC) has been improved. However, local-regional recurrence of CRC is still often noted in the patients who received radical R0-resection with no lymphatic metastasis[3].

Direct invasion, lymphatic drainage, hematogenous spread and peritoneal dissemination are the four classical routes for local-regional recurrence or distant implantation of cancer cells. In addition to these pathways, the existence of metastatic cancer cells in the mesentery of colorectum has also been reported, and this type of metastasis was named as “extra-capsular spreads” or “extra-nodal metastasis”[4-7]. In our previous study, we proposed a novel type of tumor metastasis designated as Metastasis V in gastric cancer. Metastasis V is defined as the appearance of cancer cells in the mesogastrium with perigastric adipose tissue, and it may be a risk factor for patient survival after radical surgery[8]. Here, in this study, we further determined whether Metastasis V can be detected in the mesocolonrectum, and examined its clinical significance.

MATERIALS AND METHODS
Patients, samples, and sectional tissue analysis
Sixty-three patients who underwent surgery for CRC at the Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 2012 and September 2015 were included in this study. The patients consisted of 25 female patients and 38 male patients. All of these patients received laparoscopy-assisted radical colectomy or proctectomy (with CME or TME) with R0 dissection. All participants signed informed written consents in this research. This study was approved by the Tongji Hospital Ethics Committee.

Clinical samples of CRC were obtained from the resected colorectal tissue. The location and size of the primary lesions were recorded immediately after the tumor was removed, and then the mesenterium was completely separated from the intestinal wall along with the anterior edge. All specimens were fixed in 10% formaldehyde before processing. The lymph nodes were obtained from the mesenterium. Next, the mesentery was cut into strip-shape with a width of 2 cm in an outward-to-inward manner, vertical to the intestinal wall. The strip-shaped samples were cut into cube samples with a mean length of 2 cm.
All of the small samples were numbered from inside (proximal end of the cancer) to outside (Figure 1). These samples were embedded in 10% formaldehyde.

Demographic characteristics of the 63 patients are described in Table 1. The clinicopathological stage was determined by the 7th edition of the AJCC Cancer Staging Manual.

**Immunohistochemical analysis of Metastasis V**

Immunohistochemistry was performed using the cytokeratin 19 antibody. Cytokeratin 19 is specifically expressed in intestine epithelia cells and CRC cells. Hence, it has been proven to be a highly sensitive marker for CRCs.

Immunostaining was performed by the standard streptavidin-biotin method. First, the slices were deparaffinized and rehydrated. To retrieve antigenicity, the slices were boiled in 0.01 mol/l, pH 6.0 sodium citrate buffer for approximately 15 min. Endogenous peroxidase was restrained with 0.3% hydrogen peroxide for roughly 25 min. After blocking with 3% BSA for 30 min, the anti-cytokeratin 19 monoclonal antibody was arranged in blocking buffers and the slices were incubated at 4 °C overnight. After being washed in pH 7.4 PBS 3 times (5 min each time), the corresponding secondary antibody, retained at room temperature for approximately 50 min and marked by HRP was added. After one more wash with pH 7.4 PBS for 15 min, the chromogenic reagent DAB was added to the colorate. The slices were counterstained with Harris hematoxylin, dehydrated in a graded alcohol series (75% alcohol for 6 min, 85% alcohol for 6 min, absolute ethyl alcohol I for 6 min, and absolute ethyl alcohol II for 6 min), cleared in xylene for 5 min, and mounted. Individual tumor cells in mesenteries, separated from primary lesion and lymph nodes, were identified to be Metastasis V.

**Immunohistochemistry image analysis**

Image Pro Plus Software 6.0 (Media Cybernetics, CA, United States) was used to semi-quantitatively measure the concentration of the cytokeratin 19 immunohistochemistry. This procedure, was split into six steps: (1) discovering and surveying the section of interest; (2) adjusting the optical densities; (3) obtaining, transforming and preserving images; (4) amending the background and background staining; (5) configuration of the section of interest to determine the optical density; and (6) examining optical densities.

**Statistical analysis**

The Fisher’s exact test, \( \chi^2 \) test, and Mann-Whitney U test were used to inspect the significance of the differences between the covariates. We considered a P value of less than 0.05 statistically significant. Standard statistical analyses were performed by SPSS version 20.0.

**RESULTS**

**Detection of Metastasis V in mesenterium of CRC patients**

Metastasis V was detected in 14 of the 63 (22.2%) patients by immunohistochemistry staining. These isolated cancer cells separated from the primary lesion and lymph nodes were observed in the same slice (Figure 2). In terms of “T” stage, only one case showed limited muscular layer invasion, seven cases had sub-serosal invasion, and the rest had serosal invasion. In these patients, there were three lymph node negative patients with different invasive depths (Table 2).

**Correlation between Metastasis V and clinical factors**

The demographic characteristics of patients and the pathologic features of tumors with Metastasis V are shown in Table 3. There was no significant difference
in age, gender, tumor size, and tumor location ($P > 0.05$). Metastasis V was more likely to occur in poorly differentiated tumor (5/11; 45.5%) than moderately (8/46; 17.4%) and well-differentiated one (1/6; 16.7%). The Metastasis V in the N2 stage (9/14; 64.3%) was more frequent than that in the N0 stage (3/35; 8.6%) or N1 stages (2/14; 14.3%). In addition, Metastasis V was positively related to the tumor invasive depth (T1: 0/1, 0%; T2: 1/12, 8.3%; T3: 7/39, 17.9%; T4: 6/11, 54.5%).

**Correlation between Metastasis V and preoperative CEA levels**

Previous studies have demonstrated the correlation between increased preoperative CEA and the poor prognosis of rectal cancer patients.$^{[10,11]}$. Here, we further determined the correlation between Metastasis V and preoperative CEA levels. Totally 42 CRC patients who underwent operations in our department were retrospectively studied. Metastasis V was detected in nine patients according to the pathological reports. Six patients were excluded because their preoperative CEA data was missed. The CEA levels were divided into two grades. The CEA levels more than 3 times of normal range (15.00 ng/mL) were classified as high grade, while those less than that were designated as low grade. Our data indicated that preoperative serum CEA levels in Metastasis V-positive patients were significantly higher than in Metastasis V-negative patients (4.27 ng/mL vs 3.00 ng/mL) (Table 4).

**DISCUSSION**

In this study, we have shown that metastatic cancer
Positive NS < 0.05
Metastasis V < 0.05
6
16
5
4.27
38
9
3
Metastasis V
6
0
2
9
3
NS
P
6
< 0.05
5
2
5
8
32
NS
10
Positive NS
V in these patients is strongly recommended in clinical
Therefore, immunohistochemical analysis of Metastasis
larger percentages of Metastasis V than N0 (Table 2).
Metastasis V was also correlated with lymphatic
was mainly detected in the T3 and T4 tumors (Table
related to the tumor invasion of CRC patients, which
previous studies, the incidence of Metastasis V was closely
related to the tumor invasion of CRC patients, which
mainly detected in the T3 and T4 tumors (Table 2). Metastasis V was also correlated with lymphatic
metastasis. Lymphatic nodes staging N1-N3 had
higher percentages of Metastasis V than N0 (Table 2).
Therefore, immunohistochemical analysis of Metastasis
V in these patients is strongly recommended in clinical
practice.
More interestingly, the preoperative serum CEA
levels in Metastasis V-positive patients were signifi-
cantly higher than in Metastasis V-negative patients
(4.27 ng/mL vs 3.00 ng/mL) (Table 4). These data
indicated that the prognosis of the patients with
Metastasis V-positive tumors was worse than that of
patients with Metastasis V-negative tumors. Due to
the limited number of patients in the current study, a
larger sample of cohort study should be enrolled for
further analysis.
Little is known about the exact route or mechanism
of Metastasis V. It was hypothesized that primary
tumor lesions penetrates the intestinal wall, and then
the cancer cells could probably scatter into the
fatty tissues enveloped by proper fascia. In this way,
Metastasis V occurs not only in CRC and gastric cancers,
but also in oral head-neck, pancreas and papilla of Vater
tumors[12-20].
It has been well known in practice that radical
surgery for cancers should include en bloc resection of
the primary tumor and neighboring tissues. However, it
is difficult to determine the exact boundaries of en bloc
resection within gastrointestinal tumors. "TME" or "CME"
can reduce the tumor recurrence and increase patient
survival, however, the possible reason is still unknown.
In our opinion, the mesenteries of colorectum enveloped
by the proper fascia not only propose a precise
boundary for resection, but also function as pathologic
barriers of Metastasis V spreading. Thus, our findings
are clinically significant because TME or CME should
be a useful choice for surgical excision of Metastasis V.
Further studies on the efficiency of Metastasis V excision
via TME or CME will be investigated.

Table 3 Comparison between Metastasis V-positive patients and Metastasis V-negative patients

| Parameters                  | Metastasis V | P value |
|-----------------------------|--------------|---------|
|                            | Negative     | Positive|         |
| Age (yr)                    |              |         |         |
| < 45                        | 8            | 3       | NS      |
| ≥ 45 and < 59               | 19           | 8       |         |
| ≥ 60                        | 22           | 3       |         |
| Cancer size (cm)            |              |         |         |
| < 3                         | 24           | 10      |         |
| ≥ 3 and < 5                 | 14           | 2       |         |
| ≥ 5                         | 11           | 2       |         |
| Gender                      |              |         |         |
| Female                      | 19           | 6       |         |
| Male                        | 30           | 8       |         |
| Cancer location             |              |         |         |
| Colon                       | 9            | 2       |         |
| Rectum                      | 40           | 12      |         |
| Differentiated grade        |              |         |         |
| Well                        | 5            | 1       |         |
| Moderately                  | 38           | 8       |         |
| Poorly                      | 6            | 5       |         |
| Affected lymph nodes        |              |         |         |
| N0                          | 32           | 3       | < 0.05  |
| N1                          | 12           | 2       |         |
| N2                          | 5            | 9       |         |
| Invasive depth              |              |         |         |
| T1                          | 1            | 0       | < 0.05  |
| T2                          | 11           | 1       |         |
| T3                          | 32           | 7       |         |
| T4                          | 5            | 6       |         |

Table 4 Comparison of preoperative CEA levels between Metastasis V-positive and Metastasis V-negative patients

| Parameters                  | Metastasis V | P value |
|-----------------------------|--------------|---------|
|                            | Negative     | Positive|         |
| Median (ng/mL)              | 3            | 4.27    | < 0.05  |
| Grade                       |              |         | < 0.05  |
| High (> 15.00 ng/mL)        | 5            | 5       |         |
| Low (≤ 15.00 ng/mL)         | 73           | 16      |         |

cells can reside in the mesentery of the colorectum of CRC patients. These tumor cells showed no direct attachment to the primary lesions, with no involvement of vessel-lymphatic drainage system, and are confined to the fatty tissues enveloped by the fascia proper (Figure 1). In our previous study, we proposed a novel type of tumor metastasis designated as Metastasis V in gastric cancer patients[8]. Thus, we believe that Metastasis V could be detected in the mesenteries of both gastric and CRC patients. Similar to our previous studies, the incidence of Metastasis V was closely related to the tumor invasion of CRC patients, which was mainly detected in the T3 and T4 tumors (Table 2). Metastasis V was also correlated with lymphatic metastasis. Lymphatic nodes staging N1-N3 had larger percentages of Metastasis V than N0 (Table 2). Therefore, immunohistochemical analysis of Metastasis V in these patients is strongly recommended in clinical practice.

Acknowledgments
We thank Drs. Chao-Ran Yu and Jie Shen for their helpful discussion and paper revision work.

Comments
Background
Local-regional recurrence of colorectal cancer (CRC) is still often noted in the patients who received radical R0-resection with no lymph-node metastasis.

Research frontiers
In addition to the classical four metastatic patterns, the existence of metastatic cancer cells in the mesentery of colorectum has also been reported, and this type of metastasis was named as 'extra-capsular spreads' or 'extra-nodal metastasis'. Examination of the clinical and oncological significance of isolated tumor cells found in mesentery of colorectum in CRC patients is one of the main frontiers in surgical oncology.

Innovations and breakthroughs
Metastasis V is defined as the appearance of cancer cells in the mesogastrium, and may be a risk factor for the poor prognosis after radical surgery. This study demonstrated that Metastasis V was also detected in the mesentery of colorectum, and it might be associated with the poor prognosis of CRC.
Applications

It is clinically useful to be assisted in evaluation of prognosis of CRC patients.

Peer-review

In this paper, the authors well described an interesting study about isolated cancer cells in the mesentery of colorectum (named as Metastasis V). This is an interesting point, and the issue of metastasis in patients with CRC is of main importance.

REFERENCES

1. **Hede RL**, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? *Br J Surg* 1982; 69: 613-616 [PMID: 6751457 DOI: 10.1002/bjs.1800691019]

2. **Hohenberger W**, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colon cancer: complete mesoexcision and central ligation--technical notes and outcome. *Colorectal Dis* 2009; 11: 354-364; discussion 364-365 [PMID: 19016817 DOI: 10.1111/j.1463-1318.2008.01735.x]

3. **Bovier AM**, Lauooy G, Bovier V, Rollot F, Manfredi S, Faivre J, Cotet V, Jooste V. Incidence and patterns of late recurrences in colon cancer patients. *Int J Cancer* 2015; 137: 2133-2138 [PMID: 25912489 DOI: 10.1002/ijc.29578]

4. **Myers JN**, Greenberg JS, Mo V, Roberts D. Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. *Cancer* 2001; 92: 3030-3036 [PMID: 11753980 DOI: 10.1002/1097-0142(20011215)92:12<3030::AID-CNCR10148>3.0.CO;2-P]

5. **Nakamura K**, Ozaki N, Yamada T, Hata T, Sugimoto S, Hikino H, Kanazawa A, Tokuka A, Nagaoa S. Evaluation of prognostic significance in extracapsular spread of lymph node metastasis in patients with gastric cancer. *Surgery* 2005; 137: 511-517 [PMID: 15855922 DOI: 10.1016/j.surg.2005.01.007]

6. **Etoh T**, Sasaki M, Ishikawa K, Katai H, Sano T, Shimoda T. Extramedullary metastasis is an indicator of poor prognosis in patients with gastric carcinoma. *Br J Surg* 2006; 93: 369-373 [PMID: 16392106 DOI: 10.1002/bjs.5240]

7. **Johnson JT**, Barnes EL, Myers EN, Schramm VL Jr, Borochovitz D, Sigler BA. The extracapsular spread of tumors in cervical node metastases. *Arch Otolaryngol 1981; 107: 725-729 [PMID: 7316852 DOI: 10.1001/archotol.1981.00790480001001]

8. **Xie D**, Osaiswaner H, Liu L, Wang X, Yu C, Tong Y, Hu J, Gong J. Mesogastrium: a fifth route of metastasis in gastric cancer? *Med Hypotheses* 2013; 80: 498-500 [PMID: 23403142 DOI: 10.1016/j.mehy.2012.12.020]

9. **Moll R**, Franke W, Schiller DL, Geiger B, Krepel R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. *Cell* 1982; 31: 11-24 [PMID: 6186379 DOI: 10.1016/0002-8674(82)90400-7]

10. **Sisik A**, Kaya M, Bas G, Basak F, Aliomoglu O. CEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients. *Asian Pac J Cancer Prev* 2013; 14: 4289-4294 [PMID: 23991991 DOI: 10.7314/APJCP.2013.14.7.4289]

11. **Basbug M**, Arikanoglu Z, Bulbulner N, Cetinkaya Z, Aygen E, Akbulut S, Satici O. Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer. *Hepatogastroenterology* 2011; 58: 400-405 [PMID: 2166403]

12. **Alvi A**, Johnson JT. Extracapsular spread in the clinically negative node (N0): implications and outcome. *Otolaryngol Head Neck Surg* 1996; 114: 65-70 [PMID: 8570253 DOI: 10.1016/S0194-5998(96)70285-1]

13. **Woolgar JA**, Rogers SN, Lowe D, Brown JS, Vaughan ED. Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. *Oral Oncol* 2003; 39: 130-137 [PMID: 12509965 DOI: 10.1016/S1368-8575(02)0030-1]

14. **Hirabayashi H**, Koshii K, Uno K, Ohgaki H, Nakasone Y, Fujisawa T, Syouno N, Hinohara T, Hirabayashi K. Extracapsular spread of squamous cell carcinoma in neck lymph nodes: prognostic factor of laryngeal cancer. *Laryngoscope* 1991; 101: 502-506 [PMID: 2030629 DOI: 10.1002/0005-5537-199105000-0010]

15. **Veronese N**, Luchini C, Nottegar A, Kaneko T, Sergi G, Manzato E, Solmi M, Scarpa A. Prognostic impact of extranodal extension in thyroid cancer: A meta-analysis. *J Surg Oncol* 2015; 112: 828-833 [PMID: 26943240 DOI: 10.1002/(SICI)1097-0248(200030-0)

16. **Luchini C**, Wood LD, Cheng L, Nottegar A, Stubbs B, Solmi M, Capelli P, Pea A, Sergi G, Manzato E, Fassan M, Bagante F, BollaSchweier E, Giacopuzzi S, Kaneko T, de Manzoni G, Barbaresci M, Scarpa A, Veronese N. Extramedullary extension of lymph node metastasis is a marker of poor prognosis in oesophageal cancer: a systematic review with meta-analysis. *J Clin Pathol* 2016; Epub ahead of print [PMID: 27387986 DOI: 10.1136/jclinpath-2016-203830]

17. **Veronese N**, Fassan M, Wood LD, Stubbs B, Solmi M, Capelli P, Pea A, Nottegar A, Sergi G, Manzato E, Carraro S, Maruzzo M, Cataldo I, Bagante F, Barbaresci M, Cheng L, Bencivenga M, de Manzoni G, Luchini C. Extramedullary Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis. *J Gastrointest Surg* 2016; 20: 1692-1698 [PMID: 27412320 DOI: 10.1007/s11605-016-3199-7]

18. **Veronese N**, Nottegar A, Pea A, Solmi M, Stubbs B, Capelli P, Sergi G, Manzato E, Fassan M, Wood LD, Scarpa A, Luchini C. Prognostic impact and implications of extracapsular lymph node involvement in colorectal cancer: a systematic review with meta-analysis. *Ann Oncol* 2016; 27: 42-48 [PMID: 26483050 DOI: 10.1093/annonc/mdv494]

19. **Luchini C**, Nottegar A, Pea A, Solmi M, Stubbs B, Capelli P, Sergi G, Manzato E, Fassan M, Wood LD, Scarpa A, Veronese N. Extramedullary extension is an important prognostic parameter for both colonic and rectal cancer. *Ann Oncol* 2016; 27: 955-956 [PMID: 26802150 DOI: 10.1093/annonc/mdw034]

20. **Luchini C**, Veronese N, Pea A, Sergi G, Manzato E, Nottegar A, Solmi M, Capelli P, Scarpa A. Extramedullary extension in N1 adenocarcinoma of the pancreas and papilla of Vater: a systematic review and meta-analysis of its prognostic significance. *Eur J Gastroenterol Hepatol* 2016; 28: 205-209 [PMID: 26566063]

P- Reviewer: Luchini C, Wittmann T  S- Editor: Gong ZM  L- Editor: Ma JY  E- Editor: Zhang FF
